Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772235 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL10459187 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9945534 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL29674419 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3360473 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL19509816 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL22984018 | 1.00 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL4287258 | 0.92 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9945527 | 0.90 | P2RY12 (0.41) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL15892163 | 0.89 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | ADAR, NCL, SSU72 | PDE4A 2603/4885PDE4B 3041/4885PDE4C 2418/4885 |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | ADAR, NCL, SSU72 | PDE4A 2603/4885PDE4B 3041/4885PDE4C 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.